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SUMMARY 
The aqueous extracts of three medicinal plants, Carissa edulis (Forssk.) Vahl 
(Apocynaceae), Prunus africana (Hook.f.) Kalkm (Rosaceae) and Melia azedarach L. 
(Meliaceae) have shown significant reduction in the replication of human 
cytomegalovirus (HCMV) in human embryonic lung (HEL) fibroblasts cells in vitro. 
Using the plaque inhibition assay for the determination of anti-viral activity, the HEL 
fibroblast cells cultured in 24 well plates were infected with 1 x 102 PFU 91S HCMV and 
treated with various concentrations of the extracts. The plaques formed were counted 
after 7 days incubation at 370C in 5% CO2 and the percent plaques inhibited were 
calculated against infected untreated control. The effective concentrations inhibiting 
plaque formation by 50% (EC50) was found between 40 to 80 µg/ml for all the extracts. 
The cell cytotoxic concentrations (CC50) for each of the three extracts, by the trypan blue 
exclusion test, gave a safe therapeutic index. These results have demonstrated the 
potential anti-viral activities of the extracts of the three medicinal plants at non-cytotoxic 
concentrations. 
[Afr J Health Sci. 2007; 14:143-148] 
 
Introduction 
Human cytomegalovirus (HCMV), a β-herpesvirus 
in the family herpesviridae, is found universally 
throughout all geographic locations and 
socioeconomic groups [1]. The HCMV is the virus 
most frequently transmitted to a developing child 
before birth (0.2-2.2% of all live births) [2]. For 
most healthy persons who acquire HCMV after 
birth, there are few symptoms and no long-term 
health consequences. However, HCMV infection is 
one of the most challenging complications in 
persons with lowered immune states as experienced 
after hematopoietic stem cell transplantation (SCT) 
or solid organ transplantation (SOT) [3,4] and in 
persons with Acquired Immunodeficiency 
Syndrome (AIDS) [5]. In such instances, HCMV 
disease may occur as organ involvement such as 
pneumonitis or as an indirect effect such as an 
increased risk of opportunistic infections [6,7].  
          The most widely used drugs for prophylaxis 
and treatment of HCMV infections are foscarnet, 
cidofovir and ganciclovir. Unfortunately, these 
drugs have dose limiting renal and bone marrow 
toxicities. Also the long-term therapy with these 
drugs, necessary for management of infection, has 
been associated with development of clinically 




Therefore, antiviral agents would need to be 
developed for the treatment and suppression of 
HCMV disease. 
       Natural products of plant origin are proving to 
be a valuable source for anti-viral agents 
[12,13,14]. We hereby report on extracts from three 
medicinal plants that grow in Kenya which have 
shown significant activity against HCMV in vitro. 
The plants are Carissa edulis (Forssk.) Vahl 
(Apocynaceae), Prunus africana (Hook.f.) Kalkm 
(Rosaceae) and Melia azedarach L. (Meliaceae). 
The three medicinal plants are widely used 
traditionally for treatment and management of 
various disease conditions by different 
communities in Kenya and their use in traditional 
medicine is well documented [15,16,17]. 
 
Materials and Methods 
 
Medicinal plant material collection 
The medicinal plants used in this study were 
collected with the assistance of the taxonomist, Mr. 
G.M. Mungai, from the East African Herbarium, 
Nairobi, Kenya. The plants were obtained from 
their natural habitats in different geographical 
zones of Kenya. Carissa edulis was collected from 
Gitoro forest, Meru District in Eastern Province. 
African Journal of Health Sciences, Volume 14, Number 3-4, July- December 2007 144
Prunus africana was colleted in Taita hills, Taita-
Taveta District, Coast Province and Melia 
azedarach was collected in Karura Forest, Karura, 
Nairobi Province. Voucher specimens were on 
deposit at the East African Herbarium, Nairobi, 
Kenya.   
       The stem and root barks were chopped into 
small pieces and dried at room temperature for two 
weeks. The dry barks were ground into fine powder 
using an electric mill (Christy and Norris Ltd., 
England) and stored in plastic containers at room 
temperature ready for use.  
       A 100g of stem or root bark powder was boiled 
in 1000 ml distilled water for 45 min. The resulting 
extracts were filtered and lyophilised using a 
Modulyo Freeze Dryer (Edwards, England) 
producing a free flowing powder that was weighed 
and stored in airtight containers at room 
temperature until use. Each of the freeze dried 
material was treated as follows:- A 10 mg/ml stock 
solution was prepared by dissolving 100 mg of the 
freeze-dried powder in sterile double distilled water 
and made to the 10mls mark of a volumetric flask. 
The solution was centrifuged at 3,000 rpm for 15 
min (Kubota centrifuge, Japan) to separate any un-
dissolved matter and the supernatant collected and 
filtered through a 0.45 µm membrane filter. The 
sterile filtrate was stored at 40C and used as a stock 
solution within a week.  
         For the in vitro experiments, a working 
solution of 1 mg/ml was aseptically prepared by 
diluting 100 µl stock with 900 µl (0.900 ml) 
Eagle’s Minimum Essential Medium (MEM) 
(GIBCO BRL, Scotland) supplemented with 2% 
Fetal Bovine Serum (FBS) (GIBCO BRL, 
Scotland).   
 
Viruses and cells 
The gancyclovir-sensitive clinical isolate of HCMV 
strain 91S and human embryonic lung fibroblast 
cells (HEL) were used in the study. The virus and 
cells were donated by the Kagoshima University, 
Kagoshima, Japan, through the Japan International 
Cooperation Agency (JICA). The virus was 
propagated in HEL cells of persurge numbers 
between 17 and 18. The infected cultures were 
sonicated on ice and centrifuged at 3,000 rpm for 
15 min. The virus stock (supernatant) was stored in 
35% sorbitol (Sigma) at -800C until use. The HEL 
cells were grown and maintained in Eagle’s 
Minimum Essential Medium (MEM) (GIBCO 
BRL, Scotland) supplemented with 10% (for cell 
growth) or 5% (for cell maintenance) heat 
inactivated fetal bovine serum (FBS) (GIBCO 
BRL, Scotland), kanamycin (60µg/ml), and 0.12% 
sodium hydrogen carbonate (NaHCO3) (Sigma). 
 
Reference drug gancyclovir 
Gancyclovir was used as a reference drug and was 
a donation from Prof. Yoshito Eizuru of the 
Division of Persistent and Oncogenic Viruses, 
Centre for Chronic Viral Diseases, Faculty of 
Medicine, Kagoshima University, Kagoshima, 
Japan and who was also a JICA visiting scientist at 
the Kenya Medical Research Institute (KEMRI). 
 
Plaque reduction assay 
The freeze-dried aqueous extracts of the medicinal 
plant materials were examined for extent of 
reduction of plaque formation on infected HEL 
cells in vitro. Briefly, HEL cells were cultured in 
MEM supplemented with 10% FBS to a confluent 
monolayer in 24-well plates at 37 0C in a 5% CO2 
incubator (Hirasawa Works, Japan). The culture 
medium was aspirated off aseptically and the cells 
infected with 100 plaque forming units (PFU) of 
91S HCMV. The virus was left to adsorb for 1 hr at 
room temperature on a tray shaker. The cells were 
then overlaid with maintenance medium containing 
2.25% methylcellulose (MC), 5% FBS, 0.24% 
NaHCO3 and various concentrations of freeze dried 
extracts (10 ~ 100 µg/ml) or gancyclovir at 5 
µg/ml. Each concentration was done in triplicate. 
The plate was incubated at 37 0C under 5% CO2 for 
7 days. At the end of the incubation period, the 
cells were fixed by adding 0.5ml of 5% formalin 
(Sigma) solution into each well and left to stand for 
1 hr. The media in each well was decanted and the 
cells stained with 0.03% methylene blue solution 
(Wako Pure Chemical Industries Ltd., Japan). The 
plaques, appearing as transparent dots were 
counted under a dissecting microscope with the aid 
of an electronic marker pen. The percent plaque 
inhibition was calculated and the effective 
concentrations for 50% plaque inhibition (EC50) 
were determined from a plot relating percent 
plaque inhibition against extract concentrations 
[18].   
 
Cell cytotoxicity assay 
The cell cytotoxicity of the extracts was evaluated 
in vitro by the trypan blue exclusion test as 
described elsewhere [11]. Briefly, 6x104 HEL cells 
were seeded in 24-well plates in MEM 
supplemented with 10% FBS and incubated at 370C 
in 5% CO2 to a confluent monolayer. The culture 
medium was replaced by fresh medium containing 
various concentrations of the freeze-dried extracts 
and the cells further incubated for 1 day. Each 
extract concentration was done in triplicate. The 
cells were treated with trypsin and the number of 
viable cells determined by the trypan blue 
exclusion test. The concentration of extract 
reducing cell viability by 50% (CC50) was 
determined from a curve relating percent plaque 
inhibition against concentration.   
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Data management 
 
Plaque inhibition assay 
In the plaque inhibition assay, the number of 
plaques in the infected untreated cells (control) and 
the number of plaques in the infected treated cells 
(test drug) was used for the calculation of the 
percent plaque inhibition using the formula below: 
 
% Plaque inhibition = 100% -    No.  of plaques test drug    X  100%       
                      No. of plaques control 
The percent plaque inhibition at each extract concentration was then used for the graphical determination of 
EC50.  
 
Cytotoxicity assays  
In the cell cytotoxicity determinations, the number 
of viable cells was used for the calculation of 
percent cell viability at each tested extract 
concentration. This was then used for the graphical 
determination of the cell cytotoxic concentration 
(CC50).   
 
Results 
The following results were obtained when infected 
and non-infected HEL cells were treated with the 
various concentrations of the freeze-dried plant 
extracts. Table 1 and Figure 1 show the results of 
the in vitro quantitative evaluation of anti-viral 
activity of the plant extracts in HEL cells infected 
with 91S HCMV. The following were the 
responses to various extract treatment as illustrated 
in Table 1 and Figure 1.  
 
Treatment with the Melia azedarach extract 
There was a rapid rise in plaque inhibition from 5% 
to 36% between the 10µg/ml and 20µg/ml extract 
concentrations (Figure 1). Thereafter plaque 
inhibition increased with rise in extract 
concentration, 50% of the plaques being inhibited 
at 40µg/ml (Figure 1). Table 1 shows the percent 
plaques inhibited at each tested extract 
concentration.   
 
Treatment with the Carissa edulis extract 
There was no plaque inhibition between 10µg/ml 
and 20µg/ml concentrations. However inhibition 
was observed at concentrations above 20µg/ml in a 
dose related manner. The effective concentration 
inhibiting 50% of the plaques (EC50) was at 
74.0µg/ml (Figure 1). 
 
 
                        Table 1: The percent plaque inhibition in HEL cells infected with HCMV at 1x102 
PFU/10µl and treated with extracts at various concentrations. 
   















0 0 0 0 
10 5.0 0 4.4 
20 37.0 0 9.4 
40 50.0 13.5 18.5 
60 59.0 36.5 23.0 
80 59.0 55.0 50.0 
100 68.0 68.0 60.0 
 
Human embryonic lung fibroblast cells (HEL) were seeded in 24 well plates and infected with 
1x102 PFU 91S HCMV. The infected cells were treated with various concentrations of the test 
extracts and incubated for 7 days. The numbers of plaques were counted and the percent 
plaque inhibition at each concentration calculated against uninfected control 
 
Treatment with the Prunus africana extract 
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Fig 1: Graphical determination of EC50 for the anti-91S HCMV activities of the aqueous extracts of 























Human embryonic lung fibroblast cells (HEL) were seeded in 24 well plates and infected with 1x102 
PFU 91S HCMV. The infected cells were treated with various concentrations of the test extracts and 
incubated for 7 days. The numbers of plaques were counted and the percent plaque inhibition at each 
concentration calculated. A plot relating percent plaque inhibition against concentration was 
developed and used for the determination of EC50. 
 
Cell cytotoxicity assay 
Table 2 presents the cell cytotoxic concentrations 
for 50% cell death (CC50) of the extracts in non-
infected HEL cells. The EC50 values are also 
included in this table for comparison. The results  
 
 
show that the CC50 values for all the extracts were 
above the EC50. The Melia azedarach extract was 
cytotoxic at concentrations above 80µg/ml while 
the Carissa edulis and Prunus africana extracts 
were cytotoxic at concentrations above 100µg/ml.   
                  
Table 2:  The cell cytotoxic concentrations (CC50) and the effective concentrations for 50% plaque 
inhibition (EC50) for Carissa edulis, Prunus africana and Melia azedarach aqueous extracts in 




























In the CC50 determination, the HEL fibroblast cells were seeded in 24 well plates at 
6x104 cells/well and treated with various concentrations of the extracts. The trypan 
blue exclusion test was used for evaluation of cell viability at each tested 
concentration.  The concentration of extract reducing cell viability by 50% (CC50) 
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Discussion  
The results indicate that the HCMV strain 91S used 
in the study was sensitive to all the three extracts 
examined. However, the virus was more sensitive 
to the Melia azedarach extract than to the other 
two from Prunus africana and Carissa edulis 
whose activity was almost similar (the EC50 for 
both being very close, 80µg/ml for the Prunus 
africana extract and 74µg/ml for the Carissa edulis 
extract). In an earlier investigation where the 
extracts had been examined for in vitro anti-herpes 
simplex virus type 1 and 2 activity, a significant 
antiviral activity was also observed [13]. The 
results of this study therefore show that the extracts 
have an extended antiviral activity for both the 
alpha (α) and beta (β) members of the 
herpesviridae family. This is an encouraging 
finding and calls for the determination of the mode 
of antiviral action of these extracts to compare with 
those of known antivirals such as acyclovir and its 
derivatives [19,20,21].  
       It is important to note that the medicinal 
plants whose extracts were investigated for 
antiviral activity belong to different families yet all 
of them exhibited reasonable antiviral activity. This 
indicates the possibility of the plant extracts having 
substances common in nature which poses potent 
antiviral activity. It also explains why different 
medicinal plants are used for the management of 
one single disease condition.   
 
Conclusions     
At this point, the only conclusion that can be drawn 
of these results is that the three medicinal plant 
extracts have shown potential as anti-91S HCMV 
agents in vitro. It is necessary to investigate these 
activities in vivo. Since the extracts of some of the 
plants had shown promising activity against HSV 
in both the in vitro and in vivo environments (13), it 
is envisaged that they could also do the same to the 
HCMV. If this turns out to be the case, then these 
plants could be of high potential as sources of anti-
herpesvirus agents.   
Natural products of plant origin have been 
found to contain antiviral properties worldwide 
[12,13,14,18]. Therefore there are possibilities of 
future antivirals being derived from plants or their 
constituents. This, in a way, puts Sub-Saharan 
Africa at an advantageous position due to her 
abundant resource in medicinal plants. It is 
therefore a great challenge to the scientists in the 
region to ensure that this available resource is 
tapped for the befit of our people.   
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